KT2 is a cationic amphipathic peptide modified from Crocodylus siamensis Leucrocin I. This peptide had been shown to inhibit HeLa cell viability1, 2, to induce apoptosis in HCT-116 cells both in vitro and in vivo 3-5 and to restrain HCT-116 cell migration4. The study also indicated that KT2 inhibits the migration and invasion of human melanoma cells by decreasing MMP-2 and MMP-9 expression through inhibition of FAK, uPA, MAPK, PI3K/AKT NF-kB, and RhoA–ROCK signaling pathways.
Usually ships within 24 hours.